Photo taken from Giulia Marvaso/X
Aug 25, 2024, 09:16
Giulia Marvaso: SBRT alone vs SBRT + 6 month ADT in oligorecurrent mHSPC
Università degli Studi di Milano, :
“Compliments to Giulia Marvaso and the whole RADIOSA IEO Team.
Our phase II randomized RADIOSA trial advances understanding of metastatic prostate cancer, showing that short (6 months) systemic therapy combined with metastasis-directed therapy is a winning approach.
Stay tuned for more detailed findings in the upcoming publication.”
Quoting Giulia Marvaso’s post:
“So grateful to share my interview for UroToday + GU OncToday about our RADIOSA trial.
A huge opportunity to discuss our findings of a randomized phase II trial for oligorecurrent mHSPC: SBRT alone vs SBRT + 6 months ADT.
Source: and Giulia Marvaso/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12